Modality
Vaccine
MOA
CAR-T BCMA
Target
HER2
Pathway
JAK/STAT
LGSAtopic Derm
Development Pipeline
Preclinical
Nov 2019
→ Dec 2030
PreclinicalCurrent
NCT08655160
2,835 pts·LGS
2021-02→TBD·Not yet recruiting
NCT06102748
1,931 pts·LGS
2019-11→2030-12·Terminated
4,766 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-12-124.7y awayInterim· LGS
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Preclinical
Termina…
Preclinical
Not yet…
Catalysts
Interim
2030-12-12 · 4.7y away
LGS
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08655160 | Preclinical | LGS | Not yet recr... | 2835 | HbA1c |
| NCT06102748 | Preclinical | LGS | Terminated | 1931 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn | |
| ROI-9675 | Roivant Sciences | NDA/BLA | HER2 | |
| ACA-2691 | Acadia Pharma | Phase 3 | BCMA | |
| Olpasotorasib | Structure Ther | Preclinical | C5 |